Abstract Details

Title Comparison of Patient and Caregiver Assessments of Patient Disability in Parkinson's Disease

Topic Movement Disorders

Presentation(s) P04 - (-)

Poster/Presentation
Number 186

Objective

Background BACKGROUND: Parkinson's disease (PD) is a neurodegenerative disorder that significantly impairs activities of daily living (ADLs). Most ADL questionnaires are designed for completion by caregivers in order to remain valid at a range of disability. Yet it is unknown whether caregiver responses correlate with patient responses and if caregivers' or patients' responses reflect actual levels of patient disability.

Design/Methods DESIGN/METHODS: 80 PD patients and their caregivers were recruited from the Penn Parkinson's Disease and Movement Disorders Center. Patients and caregivers completed the Penn Daily Activities Questionnaire for PD (PDAQ-PD), a 98-item forced-choice test of functional disability in PD. We also administered the Direct Assessment of Functional Status (DAFS), which involves observation of patients performing routine ADLs such as writing a check and using the phone. We administered the Mattis Dementia Rating Scale (DRS) to assess cognition and the Geriatric Depression Scale (GDS) to assess mood.

Results RESULTS: Patient and caregiver responses on the PDAQ-PD were significantly correlated (r= 0.693, p<0.05; ICC= 0.6895). Patient DRS performance (t=2.8, p <0.05) and caregiver depression (t=-2.46, p<0.05) were significant predictors of patient-caregiver disagreement on the PDAQ-PD. The DAFS correlated more strongly with caregiver (r= -0.805, p<0.05) than with patient responses on the PDAQ-PD (r= -0.675, p<0.05), but both were significantly correlated.

Conclusions CONCLUSIONS: PD patients and caregivers agreed on the patient's level of disability as measured by the PDAQ-PD. Disagreement tended to occur between caregivers and demented patients and between patients and depressed caregivers. Caregiver assessments of patient ADLs were more reflective of actual patient disability than were patients' self-reports.

Authors/Disclosures
Gyujae Choi (University of Pennsylvania) PRESENTER	No disclosure on file
Jacqueline Rick	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Rachel Goldmann Gross, MD	No disclosure on file
Daniel Weintraub	Daniel Weintraub has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Clintrex. Daniel Weintraub has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai. Daniel Weintraub has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen. Daniel Weintraub has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sage. Daniel Weintraub has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Scion. Daniel Weintraub has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Signant. Daniel Weintraub has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sunovion. Daniel Weintraub has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Modality.ai. Daniel Weintraub has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cerevel. Daniel Weintraub has received personal compensation in the range of $500-$4,999 for serving as a Consultant for CuraSen. Daniel Weintraub has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Takeda. Daniel Weintraub has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Boehringer Ingelheim. Daniel Weintraub has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Daniel Weintraub has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Acadia. Daniel Weintraub has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Movement Disorder Society. The institution of Daniel Weintraub has received research support from NIH. The institution of Daniel Weintraub has received research support from Fox Foundation. The institution of Daniel Weintraub has received research support from IPMDS. Daniel Weintraub has received intellectual property interests from a discovery or technology relating to health care.
	No disclosure on file
	No disclosure on file
Jason H. Karlawish, MD	No disclosure on file
Gioacchino Tedeschi, MD (University of Campania "L. Vanvitelli")	Dr. Tedeschi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Tedeschi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lilly. Dr. Tedeschi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis.
Andrew D. Siderowf, MD	Dr. Siderowf has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Siderowf has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Mitsubishi. Dr. Siderowf has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Boehringer-Ingelheim. Dr. Siderowf has received personal compensation in the range of $500-$4,999 for serving as a Consultant for askbio. Dr. Siderowf has received personal compensation in the range of $500-$4,999 for serving as a Consultant for capsida. Dr. Siderowf has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Parkinson Study Group. Dr. Siderowf has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Theravance. Dr. Siderowf has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurocrine. Dr. Siderowf has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Prilenia. Dr. Siderowf has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Wave. Dr. Siderowf has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Neurogastrix. Dr. Siderowf has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Prevail. Dr. Siderowf has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alerity. Dr. Siderowf has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Clintrex. Dr. Siderowf has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Inhibikase. Dr. Siderowf has a non-compensated relationship as a Scientific Advisory Board with NeuroPacs that is relevant to AAN interests or activities.

��ɫ��

��ɫ��